Short-term treatment of CIDP with efgartigimod: a case series in China
Efgartigimod demonstrates promising efficacy and safety for short-term treatment of CIDP, offering a potential alternative therapy. This study provides valuable evidence from the real-world application of efgartigimod in CIDP, and the results indicate further research is warranted.
Authors
- Yongsheng Zheng (ORCID: https://orcid.org/0000-0002-7987-4282)
- Chong Sun (ORCID: https://orcid.org/0000-0001-9008-2158)
- Kai Qiao (ORCID: https://orcid.org/0000-0001-7057-9562)
- Jie Lin (ORCID: https://orcid.org/0000-0001-6351-3389)
- Chongbo Zhao (ORCID: https://orcid.org/0000-0001-9481-1418)
- Jianian Hu (ORCID: https://orcid.org/0000-0001-9915-9983)
- Jiahong Lu (ORCID: https://orcid.org/0000-0002-1147-125X)
- Sushan Luo (ORCID: https://orcid.org/0000-0002-9033-7568)
- Jian Sun (ORCID: https://orcid.org/0000-0003-0067-5967)
- Yanyin Zhao (ORCID: https://orcid.org/0000-0001-6016-5331)
- Quanhua Meng
Institutions
- Fudan University (CN)
- Deyang Stomatological Hospital (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.3389/fimmu.2025.1533167
- Citations
- 6
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 8.34